Introduction:
Pharmascience, Canada's leading pharmaceutical company, announces an expansion of its sterile injectable manufacturing facility at the Candiac site.
Features:
This expansion marks a pivotal milestone, coinciding with the establishment of a new business unit dedicated to injectable products within Pharmascience's contract development and manufacturing organization (CDMO) services.
The creation of this specialized business unit aims to accelerate production and support Pharmascience's growth objectives by extending R&D, formulation, and manufacturing services to external pharmaceutical partners, particularly focusing on injectable products.
The expansion will triple capacity with state-of-the-art equipment, enabling annual production to surpass 20 million units and supporting more patients.
This expansion positions Pharmascience to compete globally and broaden its client base with an expanded range of products and services.
Progress on the Candiac expansion project has been commendable since its announcement last October, with Pharmascience set to invest over $120 million by 2026.
Specifications:
Name Pharmascience
Type Expansion
Year 2026
